FDA's NME Approval Rebound At Risk: Drought Of Novel Products In Line For Action In Remainder Of 2010 Could Depress Upward Trend From First Half
Executive Summary
Almost one-third fewer novel product applications are on FDA's user fee calendar for the second half of 2010 as compared to the docket at the same point in 2009, a dearth that could imperil the slow but steady improvement in annual new molecular entity and novel biologic approvals after the nadirs reached earlier in the decade
You may also be interested in...
Chart: New Molecular Entities Approved In The First Half Of 2010
New Molecular Entities Approved In The First Half Of 2010
FDA Says Lux's Uveitis Treatment Luveniq Needs Another Clinical Trial
In a "complete response" letter following the last-minute cancellation of an advisory committee review in June, FDA asks the biotech to do an additional confirmatory study.
FDA Panel Backs Broad Acute Coronary Syndromes Claim For Brilinta
An FDA advisory committee's blessing of AstraZeneca's Brilinta clinical strategy should reassure other drug developers that a single pivotal trial encompassing the spectrum of acute coronary syndromes and treatment strategies can support a broad claim for reducing thrombotic events